Brief: Q2 Sales Of Leqembi Bring BioArctic SEK 162.5 Mln In Royalty
31/07/2025 11:04
July 31 (Reuters) - BioArctic AB BIOAb.ST: SALES OF LEQEMBI® TOTALED 23.1 BILLION YEN IN THE SECOND QUARTER 2025 PARTNER'S SALES RESULTS IN ROYALTY OF SEK 162.5 MILLION WHICH, UP 280% Y/Y PARTNER'S SALES EX. STOCKPILING EFFECT WERE ABOUT JPY 17.8 BILLION, CORRESPONDING TO ROYALTY OF ABOUT SEK 125 MILLION Source text: ID:nWkrxmKTp Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln